ADT1351-Lerdelimumab Biosimilar-Anti-TGFB2 mAb-Research Grade

Catalog Number

ADT1351

Product Name

ADT1351-Lerdelimumab Biosimilar-Anti-TGFB2 mAb-Research Grade

Clonity

Monoclonal

Alternate Names

anti-mouse TGFB2 antibody,  anti-TGFB2 antibody,  anti TGFB2 antibody,  recombinant TGFB2,  TGFB2 antibody,  anti-TGFB2 monoclonal antibody,  TGFB2 antibodies,  TGFB2 recombinant antibody,  TGFB2 blocking antibody

Alias

CAT-152,  Trabio

Host

CHO Cells

Species

Human

Target

TGFB2

Gene ID

7042

Isotype

IgG4

Size

1mg, 5mg

Research Area

Immunology

CAS Number

285985-06-0

Product Description

Lerdelimumab (CAT-152,  intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2. It was being developed to reduce scarring after glaucoma drainage surgery. Development was stopped in late 2005 after unsuccessful trial results for that condition.

Mechanism of Action

Lerdelimumab is a monoclonal antibody that targets programmed cell death protein 1 (PD-1),  a receptor expressed on the surface of immune cells.

Metabolism

Lerdelimumab has a long half-life characteristic of monoclonal antibodies,  allowing for less frequent dosing. It is distributed throughout the bloodstream and various tissues.

Application

Elisa,  WB

Purity

>95% as determined by SDS-PAGE

Concentration

batch dependent

Buffer

Supplied in PBS,  PH7.5

Storage

Store at -20 °C for 12 months. Store at -80 °C for long term storage.

Shipping Condition

Shipped on ice packs.

Note

This product is for research use only.

Reactivity

Human

Reference